Lilly, Sanofi seek to sell erection drug Cialis without prescription
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Health Care & Life Sciences
Articles
Isotope maker plans $40M project in Noblesville
Radiopharmaceuticals maker Zevacor Molecular plans to open a $40 million isotope-production facility in Noblesville, creating nearly 50 good-paying jobs within five years.
Donnelly says Indiana’s VA sites not as troubled
U.S. Sen. Joe Donnelly said administrators at Indiana's VA hospitals have told him they don't have the same kind of problems as the 26 veterans facilities across the country facing complaints about long waits and backlogs.
Pfizer pulls plug on push to buy AstraZeneca
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
Hearings set for Healthy Indiana Plan expansion
Two public hearings are scheduled this week on Gov. Mike Pence's plan to use Medicaid funds to expand the Healthy Indiana Plan to provide insurance under the federal health care overhaul.
Ex-Lilly partner wins latest suit over Actos’ cancer risk
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Dropping health plan for Obamacare, this firm saved money but sacrificed choice
RANAC Corp., a small firm in Indianapolis, cut its spending on health benefits 25 percent after dropping its group health plan. Could it be a sign of things to come?
Takeda denies hiding Actos cancer risks in Nevada trial
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Pence pitches health plan proposal in Washington
The health insurance expansion Gov. Mike Pence is touting relies on federal Medicaid money and meets federal Medicaid requirements, but the Republican governor insists it's not Medicaid.
Drugmaker hid diabetes drug’s cancer risks, lawyer says
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Indiana’s Obamacare rates for 2015 all over the map
Initial 2015 premiums filed for the Obamacare exchanges in Indiana ranged from as high as a 46-percent hike to as low as a 9-percent cut. Anthem Blue Cross and Blue Shield wants an average increase of 9.7 percent.
Pence’s HIP 2.0 insurance expansion has national aspirations all over it
Gov. Pence's HIP 2.0 plan is nothing less than an attempt to roll back liberal policy on low-income health benefits as far as currently possible–and to get other states to follow suit. It might even be an opening bid for president.
Hospital plans expansion 6 years after flooding
The $30 million project at Columbus Regional Hospital will expand its emergency department and cancer center.
UPDATE: AstraZeneca board rejects new offer from Pfizer
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Lawmakers positive about Healthy Indiana Plan proposal
An expansion of the Healthy Indiana Plan, which Gov. Mike Pence announced Thursday, received overall positive reviews from Republican and Democratic lawmakers.
Cost-control plan for health care could cost more patients
The Obama administration has given the go-ahead for a new cost-control strategy called "reference pricing." It lets insurers and employers put a dollar limit on what health plans pay for some expensive procedures.
Lilly’s latest sales strategy: the soft sell
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
Marathon talks yield good deal for hospitals in Pence’s HIP expansion
Fees on hospitals will generate the lion’s share of the funds for Gov. Mike Pence’s Healthy Indiana Plan expansion. But the benefits hospitals will receive will outweigh those costs.
UPDATE: Pence unveils Healthy Indiana Plan expansion
Gov. Mike Pence said Medicaid is a "fiscal monstrosity" and hopes a proposed expansion of the state-run Healthy Indiana Plan will pass muster with federal officials as an alternative way to insure low-income residents.
Lilly loses patent dispute over Alimta in London court
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn’t breach European patents.